Skip to main content
Midas Edge

Vera Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 5, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 5, 2025

VERA$30.03-1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Statements of Stockholders’ Equity

(in thousands, except share amounts)

Class A Common Stock · AdditionalPaid-in · Accumulated Other Comprehensive · Accumulated · TotalStockholders’
Shares · Amount · Capital · Income (Loss) · Deficit · Equity
Balances as of December 31, 202463,559,858$64$1,037,948$393$(461,250)$577,155
Issuance of common stock pursuant to exercise of options100,587—982——982
Issuance of common stock upon vesting of restricted stock units90,283—————
Issuance of common stock pursuant to employee stock purchase plan23,430—551——551
Stock-based compensation——7,744——7,744
Unrealized gain on marketable securities———261—261
Net loss————(51,694)(51,694)
Balances as of March 31, 202563,774,158$64$1,047,225$654$(512,944)$534,999
Issuance of common stock pursuant to exercise of options45,162—464——464
Issuance of common stock upon vesting of restricted stock units4,345—————
Stock-based compensation——9,472——9,472
Unrealized loss on marketable securities———(127)—(127)
Net loss————(76,531)(76,531)
Balances as of June 30, 202563,823,665$64$1,057,161$527$(589,475)$468,277
Issuance of common stock pursuant to exercise of options4,882—31——31
Issuance of common stock upon vesting of restricted stock units28,390—————
Issuance of common stock pursuant to employee stock purchase plan37,908—766766
Stock-based compensation——9,745——9,745
Unrealized gain on marketable securities———354—354
Net loss————(80,293)(80,293)
Balances as of September 30, 202563,894,845$64$1,067,703$881$(669,768)$398,880
Class A Common Stock · AdditionalPaid-in · Accumulated Other Comprehensive · Accumulated · TotalStockholders’
SharesAmountCapitalIncome (Loss)DeficitEquity
Balances as of December 31, 202344,452,161$44$410,492$251$(309,102)$101,685
Issuance of common stock from underwritten follow-on offering, net of offering costs9,274,1949269,583——269,592
Issuance of common stock pursuant to exercise of options708,89716,612——6,613
Issuance of common stock upon vesting of restricted stock units938—————
Issuance of common stock pursuant to employee stock purchase plan21,181—298——298
Proceeds from short swing settlement——37——37
Stock-based compensation——4,124——4,124
Unrealized loss on marketable securities———(424)—(424)
Net loss————(28,383)(28,383)
Balances as of March 31, 202454,457,371$54$691,146$(173)$(337,485)$353,542
Issuance of common stock pursuant to exercise of options358,26513,438——3,439
Issuance of common stock upon vesting of restricted stock units937—————
Stock-based compensation——4,873——4,873
Unrealized loss on marketable securities———(277)—(277)
Net loss————(33,708)(33,708)
Balances as of June 30, 202454,816,573$55$699,457$(450)$(371,193)$327,869
Issuance of common stock pursuant to exercise of options100,628—505——505
Issuance of common stock upon vesting of restricted stock units105,597—————
Issuance of common stock pursuant to employee stock purchase plan7,763—247——247
Repurchase of common stock(4,450)—(13)——(13)
Stock-based compensation——5,588——5,588
Unrealized gain on marketable securities———1,494—1,494
Net loss————(46,632)(46,632)
Balances as of September 30, 202455,026,111$55$705,784$1,044$(417,825)$289,058
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.